Focus

Sponsors

Translating NK biology to the clinic:
a joint mission of Innate Pharma & Novo Nordisk

Novo Nordisk, Denmark, and Innate Pharma, France, have joined forces to realize first-in-class, protein-based pharmaceuticals that target receptors on natural killer (NK) cells. In close collaboration with leading academic institutions all over the world, the partnership aims to develop new treatment paradigms in immunotherapy by modulating NK cells. So far, the partnership has resulted in the world's first therapeutic monoclonal antibody targeting inhibitory killer cell immunoglobulin-like receptors (KIRs) that is now being tested in the clinic. Additional projects targeting other NK receptors are in preclinical development.

Innate Pharma, the innate immunity company, is a biotech listed on Euronext. Based on its unique products intended for treatment of cancer and immune-related disorders, as well as its R&D expertise in γδ T cells, NK cells and TLR-expressing cells, Innate Pharma intends to become a leading player in immunotherapy. Read more at http://www.innate-pharma.com.

Novo Nordisk is the global leader in diabetes care, specialized in bringing therapeutic proteins and peptides from research to market. These competences are now being used to develop a new generation of protein-based drugs for treatment of chronic inflammatory diseases. Read more at http://www.novonordisk.com.

Main navigation